<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536625</url>
  </required_header>
  <id_info>
    <org_study_id>RAPANK</org_study_id>
    <nct_id>NCT02536625</nct_id>
  </id_info>
  <brief_title>Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)</brief_title>
  <acronym>RAPANK</acronym>
  <official_title>RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Biostatistics and Therapy Evaluation Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NK (Natural Killer) cells are important in the fight against tumor, especially for the&#xD;
      control of cancer metastasis. The purpose of this prospective study is to evaluate the impact&#xD;
      on lymphocytes NK functions and development of an everolimus treatment in women treated for a&#xD;
      metastatic breast cancer. In particular, the study of lymphocytes NK functions and&#xD;
      development under everolimus treatment could permit to validate an early biomarker of the&#xD;
      impact of everolimus on these NK cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the level of Granzyme B (GzmB)</measure>
    <time_frame>Timepoint at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The objective response rate (ORR) will be defined as the proportion of patients (described on the efficacy-evaluable population) who achieve complete response (CR) or partial response (PR). ORR is based on tumor assessments (measurements according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Measured from the date of study drugs start to the date of the first objective radiological disease progression using RECIST 1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as the duration of time from start of treatment to time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intercurrent diseases reporting</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with adverse events (including infectious events) related to everolimus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating NK functions</measure>
    <time_frame>Timepoint at 3 months and at 9 months</time_frame>
    <description>Characterization of circulating NK functions by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mTOR activation status</measure>
    <time_frame>Timepoint at 3 months and at 9 months</time_frame>
    <description>rpS6 phosphorylation rate by western blot</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <description>Immunomonitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prospective study</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative) eligible for a treatment&#xD;
        with everolimus in this application&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women &gt; 18 years old&#xD;
&#xD;
          -  Metastatic breast cancer HR+ (Hormone Receptor positive), HER2/neu negative (Human&#xD;
             Epidermal Growth Factor Receptor-2)&#xD;
&#xD;
          -  ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤2&#xD;
&#xD;
          -  Eligible to an hormonotherapy treatment combined to an mTOR (mammalian Target Of&#xD;
             Rapamycin) inhibitor (i.e. SPC (Summary of Product Characteristics) modalities)&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 (Response Evaluation Criteria In Solid&#xD;
             Tumors)&#xD;
&#xD;
          -  Not receiving the non-authorized concomitant treatments&#xD;
&#xD;
          -  Patient should understand, sign, and date the written voluntary informed consent form&#xD;
             at the screening visit prior to any protocol-specific procedures performed.&#xD;
&#xD;
          -  Patients must be covered by a medical insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI&gt;30&#xD;
&#xD;
          -  All dysimmune disease, history of transplantation or immunosuppressive therapy or&#xD;
             corticotherapy&#xD;
&#xD;
          -  All chronic inflammatory diseases&#xD;
&#xD;
          -  Last chemotherapy &lt; 6 months&#xD;
&#xD;
          -  Corticotherapy &lt;1 year and more than 1 month&#xD;
&#xD;
          -  Restrictive diet ≤3 months before inclusion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TREDAN Olivier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>everolimus</keyword>
  <keyword>NK</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

